Evidence map›Paper›PMID 27807282›Full record

ArticleScience translational medicine2016

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.

Jens G Lohr, Sora Kim, Joshua Gould, Birgit Knoechel, Yotam Drier, Matthew J Cotton, Daniel Gray, Nicole Birrer, Bang Wong, Gavin Ha and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jens G LohrBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA. golub@broadinstitute.org jlohr@partners.org.
Sora KimBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Joshua GouldBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Birgit KnoechelBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Yotam DrierBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Matthew J CottonBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Daniel GrayBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nicole BirrerDivision of Hematology and Oncology/Pathology, Massachusetts General Hospital Cancer Center, MA 02114, USA.
Bang WongBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gavin HaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Cheng-Zhong ZhangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Guangwu GuoBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Matthew MeyersonBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Andrew J YeeHarvard Medical School, Boston, MA 02115, USA.
Jesse S BoehmBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Noopur RajeHarvard Medical School, Boston, MA 02115, USA.
Todd R GolubBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA. golub@broadinstitute.org jlohr@partners.org.

Funding

Determining the mutational landscape of circulating multiple myeloma cellsK08CA191026 · NCI · DANA-FARBER CANCER INST · PI LOHR, JENS G · 2015 to 2019
$886k
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemiaK08CA191091 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2015 to 2019
$886k
Howard Hughes Medical InstituteNCI NIH HHS K08 CA191026NCI NIH HHS K08 CA191091
6 · The paper itself

Abstract

Multiple myeloma (MM) remains an incurable disease, with a treatment-refractory state eventually developing in all patients. Constant clonal evolution and genetic heterogeneity of MM are a likely explanation for the emergence of drug-resistant disease. Monitoring of MM genomic evolution on therapy by serial bone marrow biopsy is unfortunately impractical because it involves an invasive and painful procedure. We describe how noninvasive and highly sensitive isolation and characterization of circulating tumor cells (CTCs) from peripheral blood at single-cell resolution recapitulate MM in the bone marrow. We demonstrate that CTCs provide the same genetic information as bone marrow MM cells and even reveal mutations with greater sensitivity than bone marrow biopsies in some cases. Single CTC RNA sequencing enables classification of MM and quantitative assessment of genes that are relevant for prognosis. We propose that the genomic characterization of CTCs should be included in clinical trials to follow the emergence of resistant subclones after MM therapy.

Indexed as

Genetic HeterogeneityBone MarrowDNA Mutational AnalysisFeasibility StudiesGene Expression ProfilingGenotypeHumansLoss of HeterozygosityMultiple MyelomaMutationNeoplastic Cells, CirculatingPlasma CellsPrognosisProof of Concept StudySequence Analysis, RNASingle-Cell Analysis

Identifiers

PMID27807282
PMCPMC5426804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.